DANIELLI, RICCARDO
 Distribuzione geografica
Continente #
NA - Nord America 1.178
EU - Europa 894
AS - Asia 178
AF - Africa 2
SA - Sud America 2
OC - Oceania 1
Totale 2.255
Nazione #
US - Stati Uniti d'America 1.174
IE - Irlanda 245
GB - Regno Unito 195
CN - Cina 118
IT - Italia 109
RU - Federazione Russa 82
SE - Svezia 70
DE - Germania 58
UA - Ucraina 44
FR - Francia 38
SG - Singapore 31
ES - Italia 20
FI - Finlandia 18
VN - Vietnam 12
KR - Corea 8
BE - Belgio 3
PL - Polonia 3
AZ - Azerbaigian 2
CH - Svizzera 2
HR - Croazia 2
IN - India 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BG - Bulgaria 1
BO - Bolivia 1
CA - Canada 1
CI - Costa d'Avorio 1
EC - Ecuador 1
EE - Estonia 1
GR - Grecia 1
HK - Hong Kong 1
JP - Giappone 1
LK - Sri Lanka 1
MX - Messico 1
SA - Arabia Saudita 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 2.255
Città #
Dublin 245
Fairfield 232
Southend 182
Ashburn 110
Woodbridge 100
Cambridge 91
Houston 91
Seattle 85
Wilmington 78
Siena 50
Chandler 46
Jacksonville 44
Ann Arbor 39
Beijing 35
Princeton 33
Shanghai 30
Málaga 20
Singapore 19
New York 18
San Mateo 18
Helsinki 16
Dearborn 14
San Diego 13
Dong Ket 11
Moscow 10
Nanjing 10
Palermo 7
Yongsan-gu 6
London 5
San Francisco 5
Venezia 5
Boardman 4
Hefei 4
Labico 4
Nanchang 4
Norwalk 4
Asciano 3
Brussels 3
Düsseldorf 3
Kunming 3
Milan 3
Pistoia 3
Redwood City 3
Baku 2
Bratislava 2
Changsha 2
Falls Church 2
Jinan 2
Saha-gu 2
Santa Clara 2
Sesto Fiorentino 2
Tianjin 2
Wandsworth 2
Zagreb 2
Zurich 2
Abidjan 1
Arezzo 1
Athens 1
Campi Bisenzio 1
Canberra 1
Chengdu 1
Chiswick 1
Colombo 1
Delhi 1
Ferentino 1
Figline Valdarno 1
Florence 1
Fremont 1
Guangzhou 1
Guayaquil 1
Hebei 1
Hendon 1
Hong Kong 1
Hounslow 1
Hyderabad 1
Islington 1
Jiaxing 1
Johannesburg 1
Kilburn 1
La Paz 1
Lanzhou 1
Mexico City 1
Naples 1
Ningbo 1
Redmond 1
Reggio Calabria 1
Reston 1
Richmond 1
Riyadh 1
Rome 1
Scarperia 1
Shinjuku 1
Sofia 1
Springfield 1
Stockholm 1
Tallinn 1
Torino 1
Toronto 1
Trieste 1
Vicenza 1
Totale 1.778
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 215
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 179
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 173
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 173
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 129
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 126
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 116
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 114
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 104
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 103
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 101
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 97
Immunotherapy targeting immune check-point(s) in brain metastases 97
Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma 96
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 90
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 85
null 75
ICOS expression as immunologic marker in immune activating monoclonal antibodies 74
null 58
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 36
Usefulness of in-vivo reflectance confocal microscopy in patient with nivolumab induced Grover disease 33
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 28
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 26
Totale 2.328
Categoria #
all - tutte 8.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.150


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020711 0 0 9 59 70 67 157 112 88 70 34 45
2020/2021453 32 31 42 18 39 85 18 77 14 42 14 41
2021/2022259 19 38 23 5 11 12 14 14 13 32 28 50
2022/2023301 21 24 54 23 10 56 10 33 20 21 16 13
2023/2024362 13 7 60 13 7 85 136 4 0 1 17 19
2024/2025110 19 25 66 0 0 0 0 0 0 0 0 0
Totale 2.328